The company makes tests with rapid time-to-results intended for high-volume hospital and pathology labs using its proprietary diagnostic technology, 3Base.
Melanoma test development firm DermTech is pulling its proposed initial public offering.
NEW YORK (GenomeWeb) — Molecular diagnostics firm Great Basin Scientific has priced a planned initial public offering of 1.15 million units, with each unit consisting of one share of common stock and one Series A warrant.
NEW YORK (GenomeWeb) – Molecular diagnostics firm AutoGenomics has refiled for an initial public offering, less than one year after it pulled earlier plans to go public.
NEW YORK (GenomeWeb) – Autoimmune rheumatic disease diagnostics firm Exagen Diagnostics filed a preliminary prospectus on Friday for an initial public offering of up to $69 million.
NEW YORK (GenomeWeb) – DermTech reported recently that it recorded $46,000 in revenues for the first six months of the year, up from none a year ago.
NEW YORK (GenomeWeb) – T2 Biosystems has launched its initial public offering of 5.2 million shares of common stock at a price of $11 per share, bringing in gross proceeds of $57.2 million.
NEW YORK (GenomeWeb) – T2 Biosystems today set a price range of between $15 and $17 per share on its planned initial public offering, with anticipated net proceeds of up to $65.9 million.
NEW YORK (GenomeWeb) – CareDx went public today with an initial public offering of 4 million shares of common stock at $10 per share.
NEW YORK (GenomeWeb) – Roka Bioscience today priced its initial public offering of 5 million shares at $12 per share, raising gross proceeds of $60 million.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.